# Sensitisation to Conventional Therapies *This section consolidates sensitisation findings covered in more detail on individual cancer-type pages.* *** Urolithin A's sensitisation properties are one of its most clinically relevant features. Across preclinical studies, Urolithin A has been shown to increase the effectiveness of chemotherapy, enhance immune-based therapies, and show preliminary evidence of radiosensitising activity. These three modalities are at very different stages of evidence and need to be read accordingly. No clinical sensitisation trials in cancer patients have yet reported results. Everything below is preclinical unless explicitly stated. *** ### Chemosensitisation This is the strongest and most consistently demonstrated sensitisation category. Urolithin A sensitises cancer cells to chemotherapy through two primary mechanisms. First, it downregulates drug-efflux transporters — MDR1, BCRP/ABCG2, MRP2, and MRP7 — that pump chemotherapy agents out of cancer cells before they can act. Reduced transporter expression means more drug stays inside the cell. Second, Urolithin A modulates the FOXO3-FOXM1 transcriptional axis, which governs drug-resistance gene-expression programmes in several cancer types. #### 5-Fluorouracil (5-FU) Urolithin A sensitises Caco-2, SW-480, HT-29, SW480, and HCT-116 colon-cancer cells to 5-FU. In 5-FU-resistant cell lines, Urolithin A restored chemosensitivity by downregulating efflux transporters and reducing 5-FU expulsion from cells. Combined Urolithin A plus 5-FU suppressed cell proliferation and invasion more effectively than 5-FU alone and produced dual-phase cell-cycle arrest — Urolithin A's G2/M arrest layered on top of 5-FU's S-phase arrest — with amplified caspase 8 and 9 activation. Confirmed synergy was established using standard combination-index methodology. #### Oxaliplatin Urolithin A demonstrated confirmed synergism with oxaliplatin in HCT116 cells, with combination-index values of 0.66–0.82, in a p53-dependent manner. This is detailed further on the colorectal-cancer evidence page. #### Paclitaxel and Cisplatin Methylurolithin A, which is a structural Urolithin A analogue, improved sensitivity of esophageal-cancer cells to both paclitaxel and cisplatin. This is analogue data rather than direct Urolithin A data. It still suggests that the chemical scaffold has chemosensitising properties across platinum and taxane classes. For the separate kidney-safety question around cisplatin nephrotoxicity, see the renal note on [Safety & Interactions](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/safety-and-interactions.md). #### Mitoxantrone Urolithin A inhibits ABCG2/BCRP-mediated mitoxantrone efflux directly, increasing intracellular accumulation of the drug. That is relevant to breast-cancer and haematological settings where BCRP-mediated resistance to mitoxantrone is documented. #### Gemcitabine In pancreatic-cancer models, Urolithin A combined with gemcitabine improved outcomes compared with gemcitabine monotherapy. No formal combination-index analysis was identified in the reviewed literature. *** ### Immunosensitisation Urolithin A modulates the immune microenvironment in ways that either directly activate anti-tumour immune responses or reduce tumour-mediated immune suppression. Both matter when thinking about immunotherapy outcomes. #### Anti-PD-1 combination — pancreatic cancer The most detailed immunosensitisation work comes from a genetically engineered mouse model of pancreatic ductal adenocarcinoma. Urolithin A reduced stromal fibrosis, which is one of the major barriers to immune-cell infiltration in pancreatic cancer, and reinvigorated adaptive T-cell responses. When combined with anti-PD-1 therapy, the Urolithin A plus anti-PD-1 combination produced enhanced CD4-positive Th1 infiltration and a statistically significant improvement in overall survival compared with anti-PD-1 alone. This is a strong preclinical finding in a model widely regarded as relevant to human pancreatic-cancer immunobiology. An NIH-funded research programme has been designed to extend this work and test whether Urolithin A can help unmask checkpoint-inhibitor responses that would otherwise be blocked by an immunosuppressive tumour microenvironment. #### Active clinical trial — checkpoint-inhibitor combination A registered clinical trial, NCT07161310, is assessing Urolithin A at 1000 mg/day in cancer patients receiving immune checkpoint inhibitors. Primary measures include cytokine profiles, T-cell transcriptional changes, and NK-cell activity. This is the only active human trial combining Urolithin A with immunotherapy. Results are pending. #### NK-cell activation — human data At 10 µM, Urolithin A increased NK-cell cytotoxic activity by an average of 23% in PBMCs from prostate-cancer patients. AhR antagonism was identified as the mechanism. This is the only published human immune-activation dataset for Urolithin A in a cancer population. It shows that the immunostimulatory effect is not confined to animal models. It does not yet prove better clinical outcomes. #### CD8-positive T-cell enhancement — human data A randomised placebo-controlled trial in middle-aged adults showed that four months of Urolithin A supplementation improved CD8-positive T-cell activation responses following stimulation, with increased TNF production and increased PGC-1α expression, a marker of mitochondrial biogenesis in immune cells. These were healthy adults rather than cancer patients. Even so, the study supports the idea that Urolithin A can produce detectable immune effects in humans at supplemental doses. #### PD-L1 reduction on tumour cells Urolithin A reduces TNF-α-induced PD-L1 expression on glioblastoma cells. Whether that translates into improved immune surveillance in vivo is still unknown. #### Important caution Urolithin A's immune-activating properties mean that concurrent use with checkpoint inhibitors could produce additive immune stimulation. That may turn out to be helpful. It could also contribute to unpredictable immune-related adverse effects. Patients on active immunotherapy should discuss Urolithin A use with their oncology team before starting. *** ### Radiosensitisation This is the least developed category and needs to be read with more caution. The only direct radiosensitisation data comes from esophageal-cancer cells. Urolithin A and methylurolithin A were tested as pretreatment before ionising-radiation exposure at doses of 200–800 cGy. Pretreatment with Urolithin A reduced cell viability after radiation compared with radiation alone. At 400 and 600 cGy, Urolithin A and methylurolithin A produced synergistic reductions in cell viability. Urolithin B did not replicate these effects, suggesting structure-specific activity. Proposed mechanisms include: * cell-cycle arrest in more radiosensitive phases * suppression of DNA-repair signalling through AKT-pathway inhibition * ROS modulation inside irradiated cells In a separate but related finding, Urolithin A has also been shown to reduce radiation pneumonitis in animal models through PINK1/Parkin-mediated mitophagy. That effect is tissue-protective rather than radiosensitising in character. The radiosensitisation evidence base is currently one cell line in one cancer type, backed by mechanistic rationale. It is worth tracking. It cannot yet be generalised confidently across tumour types or radiotherapy settings. *** ### Evidence tier summary | Modality | Cancer types studied | Evidence type | Confidence | | ------------------------------------------------------ | -------------------------- | ----------------------------------------------------- | ----------------------------- | | Chemosensitisation — 5-FU | Colorectal | In vitro, multiple lines, combination-index confirmed | Moderate preclinical | | Chemosensitisation — oxaliplatin | Colorectal | In vitro, combination-index confirmed, p53-dependent | Moderate preclinical | | Chemosensitisation — gemcitabine | Pancreatic | In vivo | Early preclinical | | Chemosensitisation — paclitaxel/cisplatin | Esophageal, analogue data | In vitro | Early preclinical | | Chemosensitisation — mitoxantrone | Breast, haematological | In vitro, transporter-focused | Early preclinical | | Immunosensitisation — anti-PD-1 | Pancreatic | In vivo, survival endpoint | Moderate preclinical | | Immunosensitisation — NK activation | Prostate | Human ex vivo, published | Preliminary human | | Immunosensitisation — CD8-positive T cells | Healthy adults | Human randomised trial, published | Preliminary human, non-cancer | | Immunosensitisation — checkpoint-inhibitor combination | Mixed cancer, active trial | Human trial ongoing | Pending | | Radiosensitisation | Esophageal | In vitro, single cell line | Very early preclinical | No clinical trials have yet reported results for chemosensitisation or radiosensitisation endpoints. The checkpoint-inhibitor combination study is active and pending. *** ### In this section * [Overview](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology.md) * [Evidence Summary](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/evidence-summary.md) * [Anticancer Mechanisms](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/anticancer-mechanisms.md) * [Immune Effects](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/immune-effects.md) * [Synergistic Combinations](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/synergistic-combinations.md) * [Urolithin A Evidence by Cancer Type](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/urolithin-a-evidence-by-cancer-type.md) * [Pharmacokinetics & Metabolism](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/pharmacokinetics-and-metabolism.md) * [Safety & Interactions](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/safety-and-interactions.md) * [Dosing & Timing](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/dosing-and-timing.md) * [Sourcing Quality Urolithin A](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/sourcing-quality-urolithin-a.md) * [Sensitisation to Conventional Therapies](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/sensitisation-to-conventional-therapies.md) * [Antimicrobial, Antiviral & Terrain Support](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/antimicrobial-antiviral-and-terrain-support.md) ### References Microbial metabolite Urolithin A acts as chemosensitizer to 5-FU in colon cancer via modulation of drug efflux transporters and FOXO3-FOXM1 axis\ Unveiling the potential of Urolithin A in cancer therapy — mechanistic insights to future perspectives\ Urolithins increased anticancer effects of chemical drugs, ionizing radiation, and hyperthermia in esophageal cancer cells\ Implications for urolithin combination therapy — radiosensitisation in esophageal cancer cells\ Remodeling of stromal immune microenvironment by Urolithin A leads to enhanced anti-tumor T-cell response and sensitisation to anti-PD-1 immunotherapy in pancreatic cancer\ Combining immunotherapy with Urolithin A to improve pancreatic cancer outcomes\ Clinical trial NCT07161310\ Urolithin A increases the natural-killer activity of PBMCs in patients with prostate cancer\ Effect of the mitophagy inducer Urolithin A on age-related immune decline\ {% hint style="warning" %} This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use. {% endhint %} {% hint style="info" %} © 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text. {% endhint %} --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/sensitisation-to-conventional-therapies.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.